Product Information
DAPTOMYCIN 350 MG VIAL is a generic product labeled by Meitheal Pharmaceuticals Inc., priced at $13.4180 per EA under NDC 71288001715. Its NADAC has been published 83 times since Dec 18, 2024.
FDA first approved this application on Jun 29, 2021. Its Orange Book therapeutic-equivalence code is AP.
Strength
350 mg/7mL
Manufacturer
Meitheal Pharmaceuticals Inc.NDC
71288001715
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
7/23/2025
Active Ingredients
DAPTOMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA213786FDA Approved
6/29/2021
TE Code
AP
On Market Since
6/29/2021
Pharmacological Classes
Price Statistics
The NADAC for DAPTOMYCIN 350 MG VIAL has been published 83 times since Dec 18, 2024, and over the history we have for it it has declined 25.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.4180 per EA |
|---|---|
| All-time high | $17.9420 (Apr 16, 2025) |
| All-time low | $13.3620 (Apr 23, 2025) |
| 52-week high | $13.4180 |
| 52-week low | $13.4180 |
| Median price | $13.4180 |
| Average price | $14.3934 |
| Largest weekly change | -25.5% (Apr 23, 2025) |
| Weeks tracked | 83 |
| Tracking since | Dec 18, 2024 |
1W
N/A
1M
N/A
3M
0.0%
6M
0.0%
1Y
0.0%
3Y
N/A
5Y
N/A
All
-25.2%
Last surveyed Jul 15, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Meitheal Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DAPTOMYCIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lipopeptide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DAPTOMYCIN 350 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for DAPTOMYCIN 350 MG VIAL, manufactured by Meitheal Pharmaceuticals Inc., is $13.4180 per EA (NDC 71288001715), effective Jul 15, 2026.
How has the price of DAPTOMYCIN 350 MG VIAL changed over time?
Over the history we have for it, the NADAC for DAPTOMYCIN 350 MG VIAL has declined 25.2%. It has been tracked across 83 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for DAPTOMYCIN 350 MG VIAL?
Since Dec 18, 2024, the NADAC for DAPTOMYCIN 350 MG VIAL has ranged from a low of $13.3620 (Apr 23, 2025) to a high of $17.9420 (Apr 16, 2025), with a median of $13.4180 per EA.
Are there cheaper alternatives to DAPTOMYCIN 350 MG VIAL?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DAPTOMYCIN 350 MG VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures DAPTOMYCIN 350 MG VIAL?
DAPTOMYCIN 350 MG VIAL (NDC 71288001715) is labeled by Meitheal Pharmaceuticals Inc., and CMS classifies it as a generic product.